 |

10 Dec 2007 - GlaxoSmithKline And OncoMed Pharmaceuticals Form Strategic Alliance To Develop Cancer Stem Cell Antibody Therapeutics
GlaxoSmithKline (GSK) and OncoMed Pharmaceuticals (OncoMed) today announced a worldwide strategic alliance to discover, develop and market novel antibody therapeutics to target cancer stem cells which are believed to play a key role in the establishment, metastasis and recurrence of cancer. The alliance with GSK will be conducted through its Center of Excellence for External Drug Discovery (CEEDD).
complete article »

27 Jul 2007 - GlaxoSmithKline and Targacept Form Alliance in Therapeutics for CNS-related Disorders
GlaxoSmithKline (GSK) and Targacept, Inc. (NASDAQ: TRGT) today announced a strategic alliance to discover, develop and market novel therapeutics that selectively target specified neuronal nicotinic receptors (NNRs).
complete article »

|

13 May 2008 - ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 Drug Represents Potential New Approach for the Treatment of Inflammatory Disease
ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX354, an orally-available, novel small molecule compound designed to specifically target the CCR1 chemokine receptor which is associated with inflammatory diseases such as rheumatoid arthritis. With the dosing of the first patient in this trial, ChemoCentryx will be entitled to receive a $10 million milestone payment from alliance partner GlaxoSmithKline (NYSE: GSK).
complete article »

6 May 2008 - Company Earns $7.5 Million Milestone From GlaxoSmithKline
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced that it has begun its Phase 2b program in Alzheimer's disease through the initiation of a clinical trial of PRX-03140, its novel 5-HT4 agonist, in combination with donepezil (Aricept(R)).
complete article »

|